ReviewJACC. CardioOncology2023
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies:
Review in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- Effects of Physical Activity on Cardiotoxicity and Cardio respiratory Function in Cancer Survivors Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- Cardio-oncology care in German hospitals: a multicentre inpatient survey of practices, perceptions and guideline gaps.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Cardiotoxicity associated with anticancer therapies for gynecological tumors.Frontiers in cardiovascular medicine · 2026Review
- Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer.Journal of gynecologic oncology · 2025Article
- Cardiovascular Consequences of Premature Menopause.Current cardiology reports · 2025Review
- Critical Care Management of Surgically Treated Gynecological Cancer Patients: Current Concepts and Future Directions.Cancers · 2025Review
- Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies.Gynecologic oncology reports · 2025Article
- Anthracycline Cardiotoxicity in Adult Cancer Patients:JACC. CardioOncology · 2024Review
- MiR-34b promotes oxidative stress and induces cellular senescence through TWIST1 in human cervical cancer.Translational oncology · 2024Article
- Cardiovascular disease and cancer: shared risk factors and mechanisms.Nature reviews. Cardiology · 2024Review
- The comparison of functional status and health-related parameters in ovarian cancer survivors with healthy controls.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements in early detection and treatment of gynecologic malignancies have led to an increasing number of survivors who are at risk of long-term cardiac complications from cancer treatment. Multimodality therapies for gynecologic malignancies, including conventional chemotherapy, targeted therapeutics, and hormonal agents, place patients at risk of cancer therapy-related cardiovascular toxicity during and following treatment. Although the cardiotoxicity associated with some female predominant cancers (eg, breast cancer) have been well recognized, there has been less recognition of the potential adverse cardiovascular effects of anticancer therapies used to treat gynecologic malignancies. In this review, the authors provide a comprehensive overview of the cancer therapeutic agents used in gynecologic malignancies, associated cardiovascular toxicities, risk factors for cardiotoxicity, cardiac imaging, and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.